Q1 2025 EPS Estimates for HealthEquity, Inc. (NASDAQ:HQY) Increased by Analyst

HealthEquity, Inc. (NASDAQ:HQY) – Equities research analysts at Zacks Research raised their Q1 2025 earnings estimates for shares of HealthEquity in a report released on Tuesday, April 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.45 per share for the quarter, up from their previous forecast of $0.43. The consensus estimate for HealthEquity’s current full-year earnings is $2.11 per share. Zacks Research also issued estimates for HealthEquity’s Q4 2025 earnings at $0.59 EPS, FY2025 earnings at $2.04 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.59 EPS, Q3 2026 earnings at $0.67 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.52 EPS.

A number of other brokerages have also recently issued reports on HQY. BTIG Research upped their target price on shares of HealthEquity from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. KeyCorp increased their price target on shares of HealthEquity from $85.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. JPMorgan Chase & Co. increased their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Royal Bank of Canada increased their price target on shares of HealthEquity from $90.00 to $92.00 and gave the company an “outperform” rating in a report on Wednesday, March 20th. Finally, Bank of America increased their price target on shares of HealthEquity from $93.00 to $97.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.17.

HealthEquity Stock Up 3.4 %

Shares of HQY stock opened at $81.30 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.76 and a current ratio of 4.76. The firm’s 50-day moving average is $80.69 and its 200-day moving average is $73.96. The stock has a market cap of $6.98 billion, a price-to-earnings ratio of 127.03, a PEG ratio of 1.30 and a beta of 0.53. HealthEquity has a 52-week low of $48.86 and a 52-week high of $84.49.

Insider Buying and Selling

In related news, CEO Jon Kessler sold 33,765 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the sale, the chief executive officer now owns 126,635 shares in the company, valued at approximately $10,106,739.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Delano Ladd sold 2,558 shares of HealthEquity stock in a transaction on Friday, March 1st. The shares were sold at an average price of $82.59, for a total transaction of $211,265.22. Following the completion of the transaction, the executive vice president now owns 47,438 shares of the company’s stock, valued at $3,917,904.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jon Kessler sold 33,765 shares of HealthEquity stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the sale, the chief executive officer now directly owns 126,635 shares of the company’s stock, valued at $10,106,739.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,322 shares of company stock worth $5,682,895. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cape Investment Advisory Inc. bought a new stake in HealthEquity in the 4th quarter worth about $27,000. Rise Advisors LLC bought a new stake in HealthEquity in the 1st quarter worth about $28,000. McGlone Suttner Wealth Management Inc. bought a new stake in HealthEquity in the 4th quarter worth about $29,000. Castleview Partners LLC bought a new stake in HealthEquity in the 2nd quarter worth about $39,000. Finally, Lazard Asset Management LLC grew its position in HealthEquity by 117.9% in the 3rd quarter. Lazard Asset Management LLC now owns 549 shares of the company’s stock worth $40,000 after purchasing an additional 297 shares in the last quarter. 99.55% of the stock is owned by institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.